Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 24,445

Document Document Title
WO/2021/089554A1
The present disclosure relates to the use of a novel dosage form of merotocin in improving lactation in a female in need thereof. The disclosure particularly provides the use of a composition suitable for intranasal administration that p...  
WO/2021/092358A1
The present inventive concept is related to a modified follicle-stimulating hormone (FSH), in particular, a hypo-glycosylated form of FSH, as well as compositions and formulations including, nucleic acids encoding, cell lines expressing,...  
WO/2021/091788A1
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in th...  
WO/2021/085518A1
The present invention discloses an aqueous pharmaceutical composition containing a protein in which serum albumin and growth hormone are linked. The aqueous pharmaceutical composition contains, as an active ingredient, a fusion protein o...  
WO/2021/055505A3
An ultra fast-acting subcutaneously injectable insulin formulation comprising a solvated complex of a diketopiperazine and a monomeric insulin in an aqueous solution at a pH of about 6.0 to about 7.2. An ultra fast-acting subcutaneously ...  
WO/2021/087035A1
An ankle-brace that incorporates an anti-rotation feature. The brace includes a conventional unified foot and ankle enclosure. One or more lateral straps are provided. Each of these straps is configured to be wrapped around the anterior ...  
WO/2021/048195A3
This invention relates to the delivery of a composition, preferably a pharmaceutical composition, comprising D-pinitol, D-Chiro inositol or myo-inositol or any pharmaceutically acceptable salt thereof, for use in the treatment or prevent...  
WO/2021/078274A1
The present invention relates to a pyridazinone or pyridazine compound and a derivative and a pharmaceutical composition thereof. Specifically, the present invention provides a pyridazinone or pyridazine compound as shown in formula (I) ...  
WO/2021/045242A3
The present invention relates to a composition which is for preventing and ameliorating or treating premenstrual syndrome symptoms, and includes: (a) a chrysanthemum sibiricum extract; (b) a mixture of the chrysanthemum sibiricum extract...  
WO/2020/189886A3
The present invention relates to biodegradable polymer microparticles containing a steroid-based drug and a preparation method therefor. Biodegradable polymer microparticles containing a steroid-based drug are prepared by a preparation m...  
WO/2021/075491A1
A transdermal absorption-type patch (10) comprises a support body (1) and an adhesive layer (2) layered on the support body (1). The adhesive layer (2) contains: a solid composite body (2a) in which an active ingredient having a molecula...  
WO/2021/073742A1
The present disclosure relates to agonists of Tacr2, such as peptides agonist of Tacr2 and methods of using the same for treatment of insulin resistance, obesity and/or diabetes. The disclosure also relates to use of said agonists of Tac...  
WO/2021/071451A1
The invention, in order to be used in the healthcare industry provided by biotechnology-nanotechnology, a targeted dual cytotoxic effective nano-metallo system for the treatment of non-metastasized castration-resistant prostate cancer, c...  
WO/2021/068239A1
Disclosed are a vaginal slow-release administration system for luteal support, a preparation method therefor and a use thereof. The system is a progesterone reservoir type vaginal ring, comprising a core layer, and a film layer double-la...  
WO/2021/069740A1
The invention relates to the field of radiation oncology. The method according to the invention comprises the use of botulinum toxin and an anticholinergic agent to prevent glands from radiation damage and side-effects due to radioligand...  
WO/2021/064421A1
The present invention relates to treatment of AR-related disorders by modulating the levels of AR2, which is a naturally occurring AR variant and is capable of modulating AR transcriptional activity.  
WO/2021/063967A1
The present invention relates to a compound of the formula (I) wherein Ar represents a phenyl or a 6-membered heteroaryl group, R1 and R2 represent independently a hydrogen atom or a deuterium atom, R3 represents (1) a -COR4 group, (2) a...  
WO/2021/062347A1
The present invention provides compositions and methods for preventing or treating pancreatitis by administering a composition comprising an effective amount of phosphate to the subject so as to treat or prevent pancreatitis in the subje...  
WO/2021/062246A1
Compounds are provided herein, as well as related preparations, compositions and methods for treating diseases and/or disorders that would benefit from the same such as congenital adrenal hyperplasia (CAH).  
WO/2021/057791A1
Provided are a chemical compound as a thyroid hormone Beta receptor agonist and a use thereof, further comprising a pharmaceutical composition containing the chemical compound. The chemical compound or pharmaceutical composition can be u...  
WO/2021/062371A1
The present disclosure is directed to a method of treating or preventing diabetes, prediabetes, and/or glucose intolerance using TNF Receptor Superfamily Member 25 (TNFRSF25) agonistic antibody or antigen binding fragment thereof. The di...  
WO/2021/054233A1
The present invention provides a biological tissue adhesive sheet having excellent tissue adhesiveness. A biological tissue adhesive sheet according to one embodiment of the present invention comprises a non-woven fabric which comprise...  
WO/2021/054866A1
The group of inventions relates to medicine, specifically to sexual pathology, and concerns increasing/restoring sexual desire (libido) and improving sexual function caused by androgen deficiency in males. Proposed is the use of 9-phenyl...  
WO/2021/051172A1
The present invention provides methods of treating metabolic diseases including obesity, insulin resistance and type 2 diabetes with inhibitors of COX-2 or VEGFR and lipid prodrugs of COX-2 inhibitors, in particular celecoxib lipid prodr...  
WO/2021/055505A2
Provided are ultra fast-acting subcutaneously injectable insulin formulations as well as a stabilized subcutaneously injectable insulin and glucagon formulations, in addition to injection systems and methods of treatments and use thereof.  
WO/2021/050945A1
Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated b...  
WO/2021/048620A1
The present invention relates to compounds of formula (I) that are capable of modulating, e.g., inhibiting or activating, one or more kinases, especially LRRK2 and/or NUAK1 and/or TYK2 or mutants thereof. The compounds are useful for tre...  
WO/2021/048618A1
The present invention relates to compounds of formula (I) that are capable of modulating, e.g., inhibiting or activating, one or more kinases, especially LRRK2 and/or NUAK1 and/or TYK2 or mutants thereof. The compounds are useful for tre...  
WO/2021/047555A1
Provided are the preparation of an aromatic heterocyclic derivative as an immunomodulator and an application thereof. Specifically, provided is a compound represented by formula I below, or an optical isomer, hydrate, solvate, or pharmac...  
WO/2021/048266A1
The present invention relates to a pharmaceutical combination, comprising (a) a pharmaceutical formulation comprising (i) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (II) insulin glargine or/and a pharmaceutically...  
WO/2021/043726A1
The disclosure provides compositions and methods for the use of oxytocin antagonists, such as substituted pyrrolidin-3-one oxime derivatives of formula (I), among other compounds, in the treatment of subjects undergoing embryo transfer t...  
WO/2020/231029A3
The present invention relates to a composition for preventing, alleviating or treating hot flush, tingling of limbs or palpitation in menopausal women, containing Lactobacillus acidophilus, and the like. It has been confirmed that, when ...  
WO/2021/045567A1
The present invention relates to a salivary gland therapeutic agent using the effects of a cell-derived vesicle of enhancing the proliferation capacity of salivary gland cells, promoting an amylase activity, and enhancing transepithelial...  
WO/2021/044302A1
The invention relates to the preparation of estetrol of formula (I), derivatives thereof protected at positions 3,15α,16α,17β of general formula (III), and 3-hydroxy derivatives thereof protected at positions 15α,16α,17β of general...  
WO/2021/043185A1
Provided herein is a compound as a thyroid hormone β receptor agonist and use thereof. It further relates to a pharmaceutical composition comprising the compound. The compound or the pharmaceutical composition can be used in the manufac...  
WO/2021/038431A1
The present invention relates to an improved process for the preparation of Etelcalcetide hydrochloride of Formula (I) : The present invention also provides a process for preparing Etelcalcetide acetate of Formula (VI), which is an inter...  
WO/2021/031991A1
A composition and a method for treating hormone-dependent diseases and reducing drug tolerance of patients with hormone-dependent diseases. The composition contains an agent capable of inhibiting expression and/or activity of 3βHSD and ...  
WO/2021/032161A1
Disclosed in the present invention are a halogen-substituted phenylate compound and applications thereof. Particularly provided are a compound shown in formula (I) or an optical isomer thereof, and pharmaceutically acceptable salts, prod...  
WO/2021/029813A1
The present invention relates to Gamma-amino butyric acid, optionally in combination with a Positive Allosteric Modulator of a GABA-receptor, for use in a method for preventing, or reducing risk of, hypoglycemia in a subject.  
WO/2021/029517A1
The present invention relates to a pharmaceutical composition for improving or treating hypoparathyroidism caused by damage to parathyroid tissue and vascular tissue around the parathyroid gland due to surgery around the neck, and a meth...  
WO/2021/028752A1
Materials and methods for treating Type 1 Diabetes (T1D) with a TNF inhibitor, e.g., wherein the TNF inhibitor is the anti-TNF antibody SIMPONI® (golimumab) having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) compri...  
WO/2021/028328A1
The present invention relates to a topical composition useful for the treatment of hair disorders such as androgenetic alopecia, hirsutism, alopecia of the eyebrow and eyelashes, hypotrichosis.  
WO/2021/025103A1
Provided is a composition capable of effectively exhibiting an effect on a change in hormonal balance. A composition is prepared which is for inhibiting reduction of testosterone and/or dihydrotestosterone and contains a cordyceps milita...  
WO/2021/025020A1
Provided is a pharmaceutical agent that increases the efficiency of drug absorption through a mucosal epithelial layer. This pharmaceutical agent for transmucosal administration contains, as an active ingredient, a pharmaceutical agent...  
WO/2021/026153A1
Uses and methods that include an effective amount of Compound A (i.e. (E)-3-(4-((1R,3R)-2-(Bicyclo[1. 1. 1]pentan-1-yl)-3-methyl- 2,3,4,9-tetrahydro-1H-pyrido[3,4-b ]indol-1-yl)-3,5-difluorophenyl)acrylic acid), or a pharmaceutically acc...  
WO/2021/023876A1
The present disclosure provides compositions and methods for treating estrogen-dependent disorders, such as disorders of the female reproductive system, including uterine fibroids and endometriosis, among others. Compounds described here...  
WO/2021/023751A1
The present invention relates to esters of Montelukast with corticosteroids, preferably with des-ciclesonide, triamcinolone, budesonide or flunisolide, pharmaceutical compositions containing the same and the use thereof in the treatment ...  
WO/2021/016929A1
Disclosed are cocrystal form A of Elagolix and pyrimethamine, a preparation method therefor and a use thereof. Using Cu-Kɑ radiation, cocrystal form A has characteristic peaks represented by a 2θ degree at 8.1±0.2°, 12.2±0.2°, 13.3...  
WO/2021/018226A1
A heterocyclic compound having the structure represented in formula I, and an application thereof. Experimental results show that the heterocyclic compound has thyroid hormone beta receptor agonistic activity, and may be used to treat an...  
WO/2021/018105A1
Provided are substituted pyrimidinedione compounds and uses thereof, as well as pharmaceutical compositions containing such compounds, which can be used as gonadotropin releasing hormone receptor antagonists. Provided are a method for pr...  

Matches 1 - 50 out of 24,445